Advertisement

Topics

Merck Sets Course for Future Growth

03:00 EDT 4 Aug 2017 | Bionity

Merck reported an increase in sales in the second quarter of 2017 along with a decline in EBITDA pre exceptionals compared with the year-earlier period. Merck confirmed its earnings guidance following the first six months of 2017. “We have set the course for future growth. By focusing on innovative ...

Original Article: Merck Sets Course for Future Growth

NEXT ARTICLE

More From BioPortfolio on "Merck Sets Course for Future Growth"

Quick Search
Advertisement
 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...


Searches Linking to this Story